Today market access starts early in the process of drug development and is driven by major pharmaceuticals markets. In Switzerland the final pricing and reimbursement decision is made by Federal Office of Public Health (FOPH). FOPH decisions are based on Federal Drug Commission recommendation. International and therapeutic benchmarking are used to set initial drug prices. We assists you in defining the pricing strategy for Switzerland, preparation and submission of the reimbursement dossier.

Target BioScience market access expertise includes:

• Market surveys
• Preparation and filing the reimbursement dossier to FOPH
• Negotiations with authorities and opinion leaders
• Search for the optimal distribution partner

We understand the unique market access and distribution requirements of orphan drugs and offer unique solutions to your challenges.